Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 524 2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

LabPsycho May. 1 at 6:34 PM

$XLO It took the A.I. Trading Bots a day to correct and refine their algorithms and realize they were supposed to be on the buy side. ✍️

0 · Reply

biohuntress May. 1 at 1:48 AM

$XLO $137.5M in estimated cash and cash equivalents as of December 31, 2025 - $40M in gross proceeds received in February 2026 from follow-on offering • Multiple opportunities to extend cash runway: - Up to $36.2M in additional gross proceeds by end of 2026 if Series C warrants exercised - AbbVie development milestones and option fees in 2026 and 2027 - Gilead option fee in 2027 ($75M)

0 · Reply

BillionerOfKing Apr. 30 at 1:59 AM

$XLO Current Stock Price: $7.80

0 · Reply

LabPsycho Apr. 29 at 2:58 PM

$XLO Don't these stupid A.I. trading bots know that the fractional microtrades here are supposed to be buys and not sells - Duh!

0 · Reply

LabPsycho Apr. 25 at 6:00 PM

$XLO @Multiplyme7x Add to your list of Biotechs that drifted below $1, then did a reverse split, sat there a while then rocketed up 200-400%: SNSE MRSN ASMB HARP

1 · Reply

Multiplyme7x Apr. 25 at 12:28 PM

$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .

0 · Reply

809trader Apr. 24 at 9:42 PM

$XLO short interest still flat. No shorts here!!

0 · Reply

Itsybitsybeanbag Apr. 23 at 7:56 PM

$MDNAF $XLO No anchoring in the TME and IL2 alpha???? If the cancer doesn’t kill ya that treatment probably will. No thanks I’ll stick with MDNA113

1 · Reply

Biotech_Pharma_Investor Apr. 23 at 6:46 PM

$MDNAF $XLO I think there may a use for both approaches

0 · Reply

biohuntress Apr. 23 at 2:00 AM

$XLO BB's getting tight...short volume today down to 13% ...maybe we'll head north soon.....maybe...maybe

0 · Reply

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Apr 16, 2026, 7:30 AM EDT - 16 days ago

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

Apr 3, 2026, 4:30 PM EDT - 4 weeks ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 23, 2026, 7:30 AM EDT - 5 weeks ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Mar 17, 2026, 4:45 PM EDT - 6 weeks ago

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Mar 12, 2026, 8:30 AM EDT - 7 weeks ago

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Mar 9, 2026, 3:00 PM EDT - 7 weeks ago

Xilio Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:00 AM EST - 2 months ago

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Feb 11, 2026, 9:34 PM EST - 2 months ago

Xilio Therapeutics Announces Pricing of Underwritten Offering

Jan 8, 2026, 8:30 AM EST - 4 months ago

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Nov 13, 2025, 7:30 AM EST - 6 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Nov 10, 2025, 4:30 PM EST - 6 months ago

Xilio Therapeutics Transcript: Status Update

Nov 7, 2025, 9:05 AM EST - 6 months ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:01 AM EST - 6 months ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Oct 30, 2025, 9:01 AM EDT - 6 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 7 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Sep 9, 2025, 7:30 AM EDT - 8 months ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Jul 2, 2025, 4:30 PM EDT - 10 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 11 months ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 11 months ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 2, 2025, 8:46 AM EDT - 11 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Jun 2, 2025, 6:11 AM EDT - 11 months ago

Xilio Therapeutics Announces Proposed Public Offering

May 31, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 9:50 AM EST - 1 year ago

Xilio Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 10:44 AM EST - 1 year ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Feb 12, 2025, 7:35 AM EST - 1 year ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 1 year ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 22, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Jan 21, 2025, 5:05 PM EST - 1 year ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Nov 7, 2024, 9:15 AM EST - 1 year ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 9:01 AM EDT - 1 year ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Xilio Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 1, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 7:05 AM EDT - 2 years ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Mar 4, 2024, 10:30 AM EST - 2 years ago

Xilio Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Feb 7, 2024, 12:30 PM EST - 2 years ago

Xilio Therapeutics Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 2 years ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dec 7, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 2 years ago

Xilio Therapeutics Transcript: Investor Update

Sep 11, 2023, 2:55 PM EDT - 2 years ago

Xilio Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 17, 2023, 12:30 PM EDT - 2 years ago

Xilio Therapeutics Transcript: Status Update

Feb 23, 2023, 9:00 AM EST - 3 years ago

Xilio Therapeutics Transcript: Citi Virtual Oncology Leadership Summit

Feb 9, 2023, 3:55 PM EST - 3 years ago

Xilio Therapeutics Transcript: Guggenheim Healthcare Talks Oncology Day

Dec 1, 2022, 12:30 PM EST - 3 years ago

Xilio Therapeutics Transcript: Status Update

Sep 13, 2022, 2:55 PM EDT - 3 years ago

Xilio Therapeutics Transcript: Morgan Stanley 20th Annual Global Healthcare Conference

LabPsycho May. 1 at 6:34 PM

$XLO It took the A.I. Trading Bots a day to correct and refine their algorithms and realize they were supposed to be on the buy side. ✍️

0 · Reply

biohuntress May. 1 at 1:48 AM

0 · Reply

BillionerOfKing Apr. 30 at 1:59 AM

$XLO Current Stock Price: $7.80

0 · Reply

LabPsycho Apr. 29 at 2:58 PM

$XLO Don't these stupid A.I. trading bots know that the fractional microtrades here are supposed to be buys and not sells - Duh!

0 · Reply

LabPsycho Apr. 25 at 6:00 PM

$XLO @Multiplyme7x Add to your list of Biotechs that drifted below $1, then did a reverse split, sat there a while then rocketed up 200-400%: SNSE MRSN ASMB HARP

1 · Reply

Multiplyme7x Apr. 25 at 12:28 PM

0 · Reply

809trader Apr. 24 at 9:42 PM

$XLO short interest still flat. No shorts here!!

0 · Reply

Itsybitsybeanbag Apr. 23 at 7:56 PM

$MDNAF $XLO No anchoring in the TME and IL2 alpha???? If the cancer doesn’t kill ya that treatment probably will. No thanks I’ll stick with MDNA113

1 · Reply

Biotech_Pharma_Investor Apr. 23 at 6:46 PM

$MDNAF $XLO I think there may a use for both approaches

0 · Reply

biohuntress Apr. 23 at 2:00 AM

$XLO BB's getting tight...short volume today down to 13% ...maybe we'll head north soon.....maybe...maybe

0 · Reply

LabPsycho Apr. 22 at 8:48 PM

$XLO @AskSmacker @809trader Wow, good luck trying to buy another $150K worth of shares without running the price up to $10 all by yourself. No complaints here though! Check out formerly HARP (Harpoon Therapeutics) also was doing masked biomolecues, also did the reverse split got down to 3 ish then bought by MRK shortly thereafter for about $20 I think. General comment on trading. A few weeks ago I suggested the bots might come in and one could tell by the strange share lots being traded. I am seeing that today.

1 · Reply

AskSmacker Apr. 21 at 5:31 PM

$XLO found this on linkedIn, worth sharing.

1 · Reply

Biotech_Pharma_Investor Apr. 21 at 4:40 PM

$MDNAF I hadnt realized they had a masked PDL1-IL2 too $XLO

0 · Reply

biohuntress Apr. 20 at 2:32 PM

$XLO xtx601 https://xiliotx.com/wp-content/uploads/2026/04/20260408_HEDGEJA1_AACR-XTX601-Poster-Final.pdf

1 · Reply

809trader Apr. 19 at 1:15 AM

$XLO data is an A+ on my book. Great efficacy and safety profile. Congrats XLO team. More details will be publish on Monday poster. 🥳🥳🥳🥳🥳🥳🥳

0 · Reply

Jtlo Apr. 17 at 8:19 PM

$XLO

1 · Reply

AskSmacker Apr. 17 at 1:27 PM

$XLO presenting Monday at 9am PST.

0 · Reply

ezimon Apr. 16 at 2:24 PM

$XLO How much longer to do I have to wait until this gets to $1.?? i.e. 0.10 cents pre-RS?

0 · Reply

8_seconds Apr. 16 at 12:32 AM

$XLO you sure are a huge pile of

2 · Reply

LabPsycho Apr. 15 at 5:27 PM

$XLO On only 10k shares traded today, I am detecting possible, very subtle, inflection point - could be the beginning of the first slope suggested in the hypothetical chart below.

1 · Reply

Shawshank256 Apr. 15 at 4:35 PM

$XLO vol

0 · Reply

ezimon Apr. 14 at 3:01 PM

$XLO 2K shares traded! WOW

0 · Reply

Market Cap	45.80M
Revenue (ttm)	43.77M
Net Income (ttm)	-35.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-80.05%
Debt to Equity Ratio	0.00

Volume	49,600
Avg Vol	38,602
Day's Range	N/A - N/A
Shares Out	5.78M
Stochastic %K	69%
Beta	-0.15
Analysts	Sell
Price Target	$20.00